HCM
NVLN

Highbridge Capital Management’s Novelion Therapeutics Inc. Common Shares NVLN Stock Holding History

Highbridge Capital Management’s Portfolio NVLN Stock Details NVLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-581,042
Closed -$421K – 92
2019
Q3 		$421K Sell
581,042
-337,300
-37% -$244K 0.06% 62
2019
Q2 		$716K Sell
918,342
-28,500
-3% -$31.7K 0.05% 118
2019
Q1 		$1.17M Hold
946,842
– – 0.04% 264
2018
Q4 		$795K Buy
+946,842
New +$1.07M 0.02% 277
2017
Q4 		– Sell
-858,144
Closed -$6.03M – 2139
2017
Q3 		$6.03M Sell
858,144
-298,462
-26% -$2.39M 0.09% 257
2017
Q2 		$10.7M Buy
1,156,606
+531,338
+85% +$5.12M 0.16% 161
2017
Q1 		$6.72M Buy
+625,268
New +$6.39M 0.1% 261

Other funds holding NVLN

SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return
FSA
Franklin Street Advisors Chapel Hill, North Carolina $1.79B AUM 28.1% 1-Year Est. Return

Highbridge Capital Management's NVLN Position: Q4 2019 in Review

Highbridge Capital Management sold out of Novelion Therapeutics Inc. Common Shares (NVLN) in Q4 2019, closing a stake of 581,042 shares — an estimated $421K sold.

Highbridge Capital Management first reported a position in NVLN in Q1 2017 and held it in 7 quarters. The position peaked at $10.7M in Q2 2017. 7 funds tracked by Wall St. Rank hold NVLN as of Q4 2019.

  • Highbridge Capital Management reported no remaining Novelion Therapeutics Inc. Common Shares position as of Q4 2019 after selling out during the quarter.
  • Highbridge Capital Management sold 581,042 Novelion Therapeutics Inc. Common Shares shares in Q4 2019, an estimated $421K.
  • Highbridge Capital Management first reported a position in Novelion Therapeutics Inc. Common Shares in Q1 2017 and held it in 7 quarters.
  • Highbridge Capital Management's Novelion Therapeutics Inc. Common Shares position peaked at $10.7M in Q2 2017.
  • 7 funds tracked by Wall St. Rank held Novelion Therapeutics Inc. Common Shares as of Q4 2019.

Based on Highbridge Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.